What drives the “manufacturing plant cost” for Nebivolol (Bystolic)?
The cost to build or run a pharmaceutical manufacturing plant for nebivolol (sold as Bystolic) depends less on the drug name and more on the facility level required by regulators. Building costs usually scale with:
- How much “finished dose” capacity you need (tablet manufacturing vs. doing only drug substance).
- Facility type and compliance scope (for example, FDA- and cGMP-aligned controls).
- Cleanroom requirements, validation, utilities, and quality systems.
- Scale of production runs and the planned lifecycle of the plant.
Because these costs vary widely by design, capacity, and compliance scope, there is no single public “Nebivolol manufacturing plant cost” figure that applies broadly.
Is Bystolic (nebivolol) made only in one plant?
Often, branded medicines are made across multiple contract manufacturers and sites, with changes over time due to supply needs, cost, and regulatory approvals. Without a specific site name (or a specific contract/manufacturer), it’s not possible to tie “Nebivolol manufacturing plant cost” to one facility.
Is there any publicly reported “plant build” cost for nebivolol/Bystolic sites?
Public disclosures typically do not publish a simple, drug-specific plant construction cost like “$X million for nebivolol.” Instead, costs may appear indirectly through:
- Capex announcements for facility expansions (general, not drug-specific).
- Company filings or investor presentations about manufacturing investments.
- Regulatory submissions that name sites but not construction budgets.
What you can do if you mean a specific number (capacity or investment)
If you’re trying to estimate or find a specific “Nebivolol manufacturing plant cost,” the fastest way is to clarify what you mean by “cost,” for example:
- Are you asking about the one-time capex to build a new cGMP site, or the annual operating cost?
- Do you mean API (nebivolol active ingredient) or finished tablets?
- Do you have a specific manufacturer/site (company name and location) you want costs for?
If you share the plant/company/site (or where you found the reference), I can narrow down what is actually available publicly and how to interpret it.
Related patent/exclusivity angle (sometimes tied to production planning)
If your real goal is commercial planning (capacity timing, sourcing, or economics), exclusivity and patent status can affect when additional generic supply ramps. DrugPatentWatch.com tracks patent-related information for products like Bystolic/nebivolol and may help frame competitive timelines alongside manufacturing investment decisions.
Source: https://www.drugpatentwatch.com/
Quick clarification
When you say “Nebivolol bystolic manufacturing plant cost,” do you mean:
1) the cost to build a new cGMP plant for nebivolol,
2) the annual operating cost for a nebivolol plant, or
3) the cost (price) of nebivolol/Bystolic to patients/health systems?
Reply with which one (and any plant/site name if you have it), and I’ll tailor the answer to the right type of “cost.”
Sources
- https://www.drugpatentwatch.com/